AVB-S6-500

DRUG5 trials

Sponsors

Aravive, Inc., Washington University School of Medicine, University of Oklahoma

Conditions

Epithelial Ovarian CancerFallopian Tube CancerHealthy VolunteerIgA NephropathyOvarian CancerPrimary Peritoneal CarcinomaUrothelial Carcinoma

Phase 1

A Phase 1 AVB-S6-500 Safety and Tolerability Study

CompletedNCT03401528

Aravive, Inc.Healthy Volunteer

Start: 2018-01-31End: 2018-07-31Updated: 2018-08-09

Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy

WithdrawnNCT03607955

Washington University School of MedicineEpithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma

Start: 2021-06-30End: 2029-08-31Updated: 2021-09-29

Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

CompletedNCT03639246

Aravive, Inc.Ovarian Cancer

Start: 2018-12-06End: 2022-12-30Updated: 2023-02-13

Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma

Active, not recruitingNCT04004442

University of OklahomaUrothelial Carcinoma

Start: 2020-02-17End: 2026-10-01Updated: 2026-03-13

Phase 2

Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy

TerminatedNCT04042623

Aravive, Inc.IgA Nephropathy

Start: 2019-11-27End: 2020-08-01Updated: 2022-02-10

Related Papers

Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma

The Oncologist2025-06-01

Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer.

2024-04-233 citations

Abstract CT506: Exposure-response analysis of batiraxcept and application to recommended phase 2 dose in platinum-resistant ovarian and clear cell renal cancers

Cancer Research2022-06-15

Phase Ib study of avelumab and novel AXL inhibitor avb-S6-500 in patients with metastatic urothelial carcinoma (mUC).

Journal of Clinical Oncology2022-06-012 citations

424 A phase 1b/2 randomized study of AVB-S6–500 in combination with cabozantinib versus cabozantinib alone in patients with advanced clear cell renal cell carcinoma who have received front-line treatment

Regular and Young Investigator Award Abstracts2021-11-012 citations

Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.

2021-08-3027 citations

Phase 1b study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma.

Journal of Clinical Oncology2021-05-20